MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux Lyon, France,…
Categorie
Press Releases
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT Independent…
July 2, 2024
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of…
June 25, 2024
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer Lyon, France, June 24th 2024 –6:00 pm CET –…
June 24, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
June 10, 2024
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, May 29 2024 –6:00 pm…
May 29, 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR…
May 15, 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR…
May 14, 2024
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024 Positive efficacy and safety data of MaaT013…
May 7, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
May 6, 2024
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.